Onvansertib for second-line treatment of KRAS-mutated mCRC

• Date :
• 2    
  0

ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors

• Date :
• 1    
  0

Impact of sex and age in esophagogastric cancer

• Date :
• 1    
  0

PLANET: pembrolizumab with lanreotide depot for advanced GEP-NETs

• Date :
• 0    
  0

DEEPER: FOLFOXIRI + cetuximab or bevacizumab for 1L mCRC

• Date :
• 0    
  0

Gallbladder & bile duct cancer at ASCO GI: GAIN and other highlights

• Date :
• 0    
  0

DPYD deficiency in patients with severe toxicity after 5-fluorouracil

• Date :
• 0    
  0

Zanidatamab: HER2-targeting bispecific antibody in HER2-expressing GEA

• Date :
• 0    
  0

Bemarituzumab + mFOLFOX6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma

• Date :
• 0    
  0

FRESCO-2: Phase III study of fruquintinib in patients with mCRC

• Date :
• 0    
  0

Total neoadjuvant therapy + pembrolizumab in locally-advanced rectal cancer

• Date :
• 0    
  0

alloSHRINK: Phase I first-in-human study evaluating CYAD-101, an allogeneic CAR-T in mCRC

• Date :
• 0    
  0

Personalizing the approach to CRC

• Date :
• 0    
  0

ctDNA as a novel biomarker for MRD in CRC

• Date :
• 0    
  0

KEYNOTE-062: pembrolizumab vs. chemo in 1L advanced gastric cancer

• Date :
• 0    
  0

Real-world outcomes of patients with intrahepatic CCA treated with trans-arterial radioembolization

• Date :
• 0    
  0

Outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in HCC

• Date :
• 0    
  0

Final results from ClarIDHy

• Date :
• 0    
  0

Next-generation sequencing and emerging targets

• Date :
• 0    
  0

Landscape of actionable somatic alterations in advanced CCA

• Date :
• 0    
  0

ASCO GI 2021: biomarker-driven research, radiomics & CAR-T

• Date :
• 0    
  0

Areas of unmet need for patients with GI malignancies

• Date :
• 0    
  0

NEO-Nal-IRI: liposomal irinotecan + 5-FU & oxaliplatin in panceratic cancer

• Date :
• 0    
  0

Adjuvant therapy for esophageal cancer

• Date :
• 0    
  0

ICONIC: FLOT-A in resectable oesophagogastric adenocarcinoma

• Date :
• 0    
  0

Precision medicine at ASCO GI 2021

• Date :
• 0    
  0

Immuno-oncology in MSI colorectal cancer

• Date :
• 0    
  0

Managing patients with CRC using ctDNA

• Date :
• 0    
  0

Challenges in using immuno-oncology for GI malignancies

• Date :
• 0    
  0

Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies

• Date :
• 0    
  0

Latest news in gastric cancer from ASCO GI

• Date :
• 0    
  0

The SMART study: IRE in pancreatic cancer

• Date :
• 0    
  0

Detecting resistance to EGFR rechallenge in RAS/RAF WT CRC

• Date :
• 0    
  0

CONVERSION from unresectable to resectable mCRC in real-world patients

• Date :
• 0    
  0

Promising results from the gastric cancer cohort of LEAP-005

• Date :
• 0    
  0

Infigratinib in previously treated advanced CCA

• Date :
• 0    
  0

Unmet needs in NETs

• Date :
• 0    
  0

Phase I study of OBP-301 for locally advanced esophageal cancer

• Date :
• 0    
  0

Liposomal irinotecan + fluorouracil/leucovorin after progression in mPDAC

• Date :
• 0    
  0

Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

• Date :
• 0    
  0

CRT-induced molecular alterations and associated outcomes in patients with rectal cancer

• Date :
• 0    
  0

Computerized food frequency questionnaire to assess dietary patterns in advanced GI cancers

• Date :
• 0    
  0

KEYNOTE-224: pembrolizumab monotherapy for previously untreated HCC

• Date :
• 0    
  0

Niraparib in BAP1 and DDR pathway deficient solid tumors

• Date :
• 0    
  0

Impact of socioeconomic status on CRC patient survival

• Date :
• 0    
  0

Personalizing ctDNA analysis to predict CRC relapse

• Date :
• 0    
  0

FDA considerations for approval of therapies in GI cancers

• Date :
• 0    
  0

Real-world safety of second-line 5-FU regimens in mPDAC

• Date :
• 0    
  0

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

• Date :
• 0    
  0

Improving diversity in clinical trial enrollment

• Date :
• 0    
  0

KEYNOTE-177 & Checkmate142: checkpoint blockade in MSI-H/dMMR CRC

• Date :
• 0    
  0

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

• Date :
• 0    
  0

Challenges in the approval of therapies for GI cancers

• Date :
• 0    
  0

MSI in patients with stage III colon cancer receiving 5-FU with or without oxaliplatin

• Date :
• 0    
  0

Impact of COVID-19 on the regulatory approval process

• Date :
• 0    
  0

Prognostic value of tumor deposits in stage III colon cancer patients

• Date :
• 0    
  0

ASCO GI 2021: HER2-positive gastric cancer, POLO and key trials in progress

• Date :
• 0    
  0

Disparities in access to screening and variation of targets in different groups

• Date :
• 0    
  0

Lenvatinib and pembrolizumab in microsatellite stable CRC

• Date :
• 0    
  0

Regorafenib plus pembrolizumab for first-line treatment of advanced HCC

• Date :
• 0    
  0

Future directions & unmet needs in HCC

• Date :
• 0    
  0

KEYNOTE-240: pembrolizumab in advanced HCC

• Date :
• 0    
  0

90Y-FF-21101: a P-cadherin-targeting antibody in advanced CRC

• Date :
• 0    
  0

Gender representation in authorship in later-phase clinical trials in BTC

• Date :
• 0    
  0

Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

• Date :
• 0    
  0

Molecular profiling of esophagogastric cancer patient-derived xenografts

• Date :
• 0    
  0

DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

• Date :
• 0    
  0

Phase III study of NUC-1031 for first-line treatment of CCA

• Date :
• 0    
  0

Trials in progress presented at ASCO GI 2021

• Date :
• 0    
  0

LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

• Date :
• 0    
  0

KEYNOTE-177: translating results for patients and clinicians

• Date :
• 0    
  0

Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer

• Date :
• 0    
  0

Pembrolizumab vs. chemo in first-line mCRC

• Date :
• 0    
  0

AI-based online search tool to increase patients’ access to GI clinical trials

• Date :
• 0    
  0

MAHOGANY: margetuximab in gastric cancer

• Date :
• 0    
  0

TAGS: impact of prior therapies on outcomes with trifluridine/tipiracil

• Date :
• 0    
  0

Genomic pathway of gut microbiome predicts efficacy of nivolumab in advanced GC

• Date :
• 0    
  0

GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors

• Date :
• 0    
  0

KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers

• Date :
• 0    
  0

Long-term results from CheckMate 040: nivolumab + ipilimumab in advanced HCC

• Date :
• 0    
  0

Prognostic value of body weight loss in previously treated metastatic gastric cancer

• Date :
• 0    
  0

Key challenges in the treatment of colorectal cancer

• Date :
• 0    
  0

MOUNTAINEER-02: tucatinib in previously treated HER2+ gastric cancer

• Date :
• 0    
  0

TAGS: trifluridine/tipiracil in metastatic gastric adenocarcinoma

• Date :
• 0    
  0

Next steps in gastric cancer

• Date :
• 0    
  0

KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC

• Date :
• 0    
  0

Health-related quality of life in young CRC survivors

• Date :
• 0    
  0

Evaluating the use of liquid biopsies in CRC

• Date :
• 0    
  0

ARC-8: AB680 + zimberelimab for first-line mPDAC

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4178    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3838    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3169    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6927    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2504    
  0